[go: up one dir, main page]

WO2005089749A3 - Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee - Google Patents

Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee Download PDF

Info

Publication number
WO2005089749A3
WO2005089749A3 PCT/FR2005/000369 FR2005000369W WO2005089749A3 WO 2005089749 A3 WO2005089749 A3 WO 2005089749A3 FR 2005000369 W FR2005000369 W FR 2005000369W WO 2005089749 A3 WO2005089749 A3 WO 2005089749A3
Authority
WO
WIPO (PCT)
Prior art keywords
metronidazole
disorder
treating
preparing
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/000369
Other languages
English (en)
Other versions
WO2005089749A2 (fr
Inventor
Fabrizio Dolfi
Irina Safonova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to JP2006553617A priority Critical patent/JP2007523132A/ja
Priority to EP05729333A priority patent/EP1732542A2/fr
Priority to BRPI0506557-7A priority patent/BRPI0506557A/pt
Priority to US10/590,074 priority patent/US20070238772A1/en
Priority to CA002554637A priority patent/CA2554637A1/fr
Priority to AU2005224122A priority patent/AU2005224122A1/en
Publication of WO2005089749A2 publication Critical patent/WO2005089749A2/fr
Publication of WO2005089749A3 publication Critical patent/WO2005089749A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention se rapporte à l’utilisation du métronidazole pour la préparation d’une composition pharmaceutique, destinée au traitement d’un désordre de la vascularisation cutanée, plus particulièrement la rosacée.
PCT/FR2005/000369 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee Ceased WO2005089749A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006553617A JP2007523132A (ja) 2004-02-20 2005-02-17 皮膚の血管新生疾患を治療するための医薬組成物の調製における、メトロニダゾールの使用
EP05729333A EP1732542A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee
BRPI0506557-7A BRPI0506557A (pt) 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica
US10/590,074 US20070238772A1 (en) 2004-02-20 2005-02-17 Use of Metronidazole for Preparing a Pharmaceutical Composition for Treating a Cutaneous Vascularisation Disorder
CA002554637A CA2554637A1 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d` un desordre de la vascularisaton cutanee
AU2005224122A AU2005224122A1 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR04/01720 2004-02-20
FR0401720A FR2866568B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee

Publications (2)

Publication Number Publication Date
WO2005089749A2 WO2005089749A2 (fr) 2005-09-29
WO2005089749A3 true WO2005089749A3 (fr) 2006-05-04

Family

ID=34833945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/000369 Ceased WO2005089749A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee

Country Status (11)

Country Link
US (1) US20070238772A1 (fr)
EP (1) EP1732542A2 (fr)
JP (1) JP2007523132A (fr)
KR (1) KR20060124708A (fr)
CN (1) CN1921850A (fr)
AU (1) AU2005224122A1 (fr)
BR (1) BRPI0506557A (fr)
CA (1) CA2554637A1 (fr)
FR (1) FR2866568B1 (fr)
RU (1) RU2006133535A (fr)
WO (1) WO2005089749A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184354A1 (en) * 2009-01-23 2016-06-30 Jr Chem, Llc Rosacea treatments and kits for performing them
CN117838651B (zh) * 2023-12-08 2025-09-23 河北君临药业有限公司 一种人工牛黄甲硝唑胶囊的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
CA2161737A1 (fr) * 1995-10-30 1997-05-01 Richard J. Mackay Gel de metronidazole
WO1998027960A2 (fr) * 1996-12-20 1998-07-02 Bioglan Ireland (R & D) Limited Composition gelifiee a base de nitro-imidazole
WO2004112780A1 (fr) * 2003-06-18 2004-12-29 Galderma S.A. Composition pharmaceutique topique de teinte verte a base de metronidazole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
CA2161737A1 (fr) * 1995-10-30 1997-05-01 Richard J. Mackay Gel de metronidazole
WO1998027960A2 (fr) * 1996-12-20 1998-07-02 Bioglan Ireland (R & D) Limited Composition gelifiee a base de nitro-imidazole
WO2004112780A1 (fr) * 2003-06-18 2004-12-29 Galderma S.A. Composition pharmaceutique topique de teinte verte a base de metronidazole

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOUNT B W ET AL: "Rosacea: A common, yet commonly overlooked, condition", AMERICAN FAMILY PHYSICIAN 01 AUG 2002 UNITED STATES, vol. 66, no. 3, 1 August 2002 (2002-08-01), pages 435 - 440+442, XP008036105, ISSN: 0002-838X *
COHEN A F ET AL: "Diagnosis and treatment of rosacea", JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE 2002 UNITED STATES, vol. 15, no. 3, 2002, pages 214 - 217, XP008036097, ISSN: 0893-8652 *
EGAN C A ET AL: "Rosacea induced by beclomethasone dipropionate nasal spray", INTERNATIONAL JOURNAL OF DERMATOLOGY 1999 UNITED KINGDOM, vol. 38, no. 2, 1999, pages 133 - 134, XP008036086, ISSN: 0011-9059 *
MADDIN S: "A COMPARISON OF TOPICAL AZELAIC ACID 20% CREAM AND TOPICAL METRONIDAZOLE 0.75% CREAM IN THE TREATMENT OF PATIENTS WITH PAPULOPUSTULAR ROSACEA", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 40, no. 6, PART 1, June 1999 (1999-06-01), pages 961 - 965, XP008016063, ISSN: 0190-9622 *
MOULIN G ET AL: "Rhinophyma", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 1991 FRANCE, vol. 118, no. 4, 1991, pages 319 - 322, XP008036089, ISSN: 0151-9638 *
ROHRICH R J ET AL: "Rhinophyma: Review and update", PLASTIC AND RECONSTRUCTIVE SURGERY 01 SEP 2002 UNITED STATES, vol. 110, no. 3, 1 September 2002 (2002-09-01), pages 860 - 870, XP008036088, ISSN: 0032-1052 *

Also Published As

Publication number Publication date
CN1921850A (zh) 2007-02-28
AU2005224122A1 (en) 2005-09-29
CA2554637A1 (fr) 2005-09-29
WO2005089749A2 (fr) 2005-09-29
EP1732542A2 (fr) 2006-12-20
FR2866568B1 (fr) 2007-08-24
KR20060124708A (ko) 2006-12-05
FR2866568A1 (fr) 2005-08-26
US20070238772A1 (en) 2007-10-11
BRPI0506557A (pt) 2007-04-17
JP2007523132A (ja) 2007-08-16
RU2006133535A (ru) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2007115821A3 (fr) Composés organiques
WO2007093627A3 (fr) Composition biocide
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2007127263A3 (fr) Utilisations thérapeutiques d'urolithines
WO2008067219A3 (fr) Modulateurs quinazolinones de tgr5
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2009156462A3 (fr) Composés organiques
WO2007025613A3 (fr) Utilisation de composes se liant au recepteur sigma pour traiter la douleur associee au diabete
WO2007130822A3 (fr) Modulateurs des récepteurs mglur5 iii
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2006124713A3 (fr) 4-biarylyl-1-phenylazetidin-2-ones
WO2009007532A3 (fr) Utilisation d'une hemoglobine pour la preparation de pansements, et pansements ainsi prepares
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2006018184A3 (fr) Derives de cyclohexane spirocycliques
WO2007144057A3 (fr) Carbone antimicrobien
WO2009011910A3 (fr) Composés d'imidazolidinone, procédés pour inhiber une désubiquitination et procédés de traitement
WO2007022947A3 (fr) Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
WO2009111785A3 (fr) Traitement d’une septicémie avec 5-éthyl-1-phényl-2(1h)-pyridone et nouveaux procédés de synthèse
WO2006023843A3 (fr) Nouveaux hétérocycles
WO2008098143A3 (fr) Composés antimicrobiens et leurs procédés d'utilisation
WO2007115287A3 (fr) Combinaison de composés organiques
WO2005089749A3 (fr) Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005729333

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2554637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200606665

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005224122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009315

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006553617

Country of ref document: JP

Ref document number: 1020067016589

Country of ref document: KR

Ref document number: 4753/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580005570.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005224122

Country of ref document: AU

Date of ref document: 20050217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005224122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006133535

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067016589

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005729333

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10590074

Country of ref document: US

Ref document number: 2007238772

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0506557

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2005729333

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10590074

Country of ref document: US